Abstract
INTRODUCTION
As a type of intra-cerebral neoplasm, gliomas are derived from the glial cells of the brain or the spine. According to the World Health Organization (WHO), gliomas can be classified into four malignancy grades I-IV [1] [2] [3] . Malignant gliomas are classified as a type of grade IV tumor, which are the most aggressive and highlyinvasive tumors of the central nervous system with an annual incidence rate of approximately 0.03 -0.05 % worldwide [4, 5] . As the most common type of malignant glioma, glioblastoma multiforme (GBM) is another category of glioma, accounting for 30 % of primary brain tumors [6] . Despite recent advancements in the treatment of GBM, the clinical prognosis of GBM patients remains poor. Following the standard-of-care treatment, such as surgical resection and chemoor radio-therapy, GBM patients obtain a median survival of 15 months. The 5-year survival rate merely achieves 3.3 % [7, 8] .
Statins are common prescription drugs to lower the serum level of lipid, treat dyslipidemias and prevent cardiovascular diseases [9] . In addition, statins have been proven to exert multiple biological functions including anti-inflammation [10] , anti-oxidant [11, 12] , angiogenic and vascular protection [13, 14] , and anti-cancer effects [15] [16] [17] [18] [19] . Previous studies have indicated the potential chemo-preventive role of statins upon the risk of malignant tumors and statins can reduce the mortality rate of cancer patients and the incidence rate of gliomas [15] [16] [17] [18] [19] [20] [21] [22] . Previous laboratory studies have demonstrated that statins can exert anti-tumor effect through inhibiting the growth, cellular proliferation and migration by inducing cellular apoptosis [15, 18, [23] [24] [25] [26] . In this article, we summarized the most recent studies related to the role of statins in gliomas, aiming to unravel the potential mechanism underlying the anti-glioma effect of statins.
-----------------------------------------------------------------------------------------------------------------------------------------------------

EFFECT OF STATINS ON GLIOMA CELL PROLIFERATION
As a type of primary intra-cerebral tumor, the clinical prognosis of patients diagnosed with gliomas is still poor mainly due to the alarmingly high proliferation rate of glioma cells. How to suppress and prevent the rapid proliferation of glioma cells has captivated widespread attentions from the oncologists. Previous studies have demonstrated that statins are able to suppress the invasion and growth of HMG-CoA-R and glioma cells and function to induce the cellular apoptosis [28, 29] . Recent studies have indicated that the incidence of glioma is considerably decreased in those who are administered with long-term statins. Moreover, statins can promote the apoptosis of glioma cells and suppress the proliferation of tumor cells [18, [25] [26] [27] .
Fas translocation and PI3K/Akt/mTOR, caspase-3 PI3K/Akt signaling pathway is involved in the proliferation, migration and invasion of glioma cells [30] . Wu et al [25] have proposed that simvastatin can suppress the cellular proliferation and migration, and induce the apoptosis of U87 and U251 cells in a dose-and time-dependent pattern. Simvastatin is capable of lowering the cholesterol level on the glioma cell membrane, disrupting the structure of lipid rafts and downregulating the PI3K/Akt pathway. Additionally, the signaling mechanism of Fas translocation and PI3K/Akt/caspase-3 pathway is involved with the anti-tumor effects of simvastatin. Maja Misirkica et al [31] have also demonstrated that simvastatin can mediate the induction of Beclin-1 and autophagy of glioma cells are correlated with the down-regulation of basal mTOR activity.
Simvastatin has been proven to trigger the AMPK/Akt/mTOR autophagy, prevent glioma cells from apoptotic death. In addition, statins have been validated to induce cell autophagy and regulate cell necrosis [32] [33] [34] [35] . Therefore, Akt-related molecular signaling pathways are of vital significance in the proliferation of glioma cells.
HMG CoA reductase specifically suppresses the expression of Akt by inhibiting AMPK or PI3K activity, thereby suppressing the cell autophagy pathway and promoting the necrosis of glioma cells, as illustrated in Figure 1 . 
JNK/ATF-2 signaling pathway
JNK/ATF-2 molecular signaling pathway is intimately correlated with cell proliferation. The trans-activation capacity of N-terminal domains of c-jun and ATF-2 is strengthened via the phosphorylation of JNK and p38 kinase [36] . ATF-2 is involved in JNK-and p38 kinasedependent ATF-2 N-terminal phosphorylation to cell stress, which has been validated in multiple cellular stress responses [37] . Meral Koyuturk et al [38] have also demonstrated that simvastatin can reduce cell proliferation and induce apoptotic death in C6 glioma cells in a time-and concentration-dependent pattern. The mechanism is the simvastatin-induced activation of JNK in glioma cells via the induction of c-jun and the activation of ATF-2. Subsequently, the death of glioma cells is aggravated. Ohba et al [39] have found that similar molecular mechanisms of c-Jun-associated responses are vital events in the cyto-protection of temozolomide (TMZ)-treated glioma cells mediated by JNK.
TRAIL signaling pathway
The tumor necrosis factor-related apoptosisinducing ligand (TRAIL) is a member of the TNF super-family, and able to bind to death receptors including DR5 and DR4, thereby inducing cell apoptosis in multiple cancer cells but inducing no harm to normal cells [40] [41] [42] . David et al [42] have demonstrated that lovastatin can sensitize the TRAIL-induced cell death, and two of the tested glioblastoma cell lines are resistant to TRAIL-induced apoptosis. Therefore, lovastatin can sensitize glioblastoma cells via the effect upon the TRAIL receptor signaling pathway, and equally triggers an unknown mechanism.
Lovastatin is a cytostatic agent that supports TRAIL-induced cell apoptosis in glioblastoma cells. TRAIL-induced cell death mechanism has been evaluated in the colon and pulmonary tumors [43] . Combined regime of TRAIL, nonchemotherapeutic agents and statins might provide a potentially novel option for the clinical treatment of gliomas.
Raf/MEK/ERK signaling pathway
Changes in the Ras/Rho-mediated signaling transduction, including the Ras-Raf-MEK-ERK signaling pathway, play a central role in the molecular pathogenesis of GBM [5, 18] . Sarah et al [18] have reported that lovastatin and perillyl alcohol disrupt the regulatory effect of Ras-Raf-MEK-ERK and MVA-and the signaling pathways in U343 and U87 cells, which equally affect the modification of H-Ras and Rac1 post-translation, and data on these compounds strengthen the effect of isoprenoids FPP and GGPP upon modification of small GTPases post-translation and accelerating the proliferation of glioma cells. Statins plays an essential role in alternative types of cancer.
Wu et al [44] have found that statins are able to trigger cell apoptosis by regulating the Raf/MEK/ERK signaling pathway. Downregulating the Raf/MEK/ERK signaling pathway can potentiate cell apoptosis induced by statins when exposed to D98059, a MEK1 inhibitor and can sensitize AML cells to a low concentration of lovastatin. Du et al [45] have demonstrated that cell apoptosis induced by dihydroartemisinin is accompanied with the PI3K/AKT and Raf/MEK/ERK signaling pathway inactivation, besides down-regulating the expression of Mcl-1 and Bcl-2, anti-apoptotic proteins. Roberts et al [46] have demonstrated that dys-regulation of the Raf/MEK/ERK signaling pathway is correlated with the incidence of multiple types of human tumors and suppressing the Raf/MEK/ERK signaling pathway serves as a novel option for cancer management.
Alternative signaling pathways
Previous studies have proposed multiple mechanisms and molecular signaling pathways are associated with the effect of statins upon inducing the apoptosis of glioma cells. However, which signaling pathway plays the most pivotal role in these events have been largely unknown. Accumulated recent evidence has demonstrated that the cell autophagy-related signaling pathways, such as the PI3K/Akt/mTOR and MAPK signaling pathways, exert the primary effect upon the death and apoptosis of glioma cells [32] [33] [34] [35] 47] .
EFFECT OF STATINS ON GLIOMA CELL INVASION
Cancer invasion is a very important indicator in terms of evaluating the cancer malignancy. Recent studies have shown that microglia can promote the growth of glioma cells [48] . Glioma cells can activate the microglia to express matrix metalloprotease (MMPs), which can promote the glioma cell invasion. Some studies have also demonstrated that atorvastatin can downregulate the expression levels of matrix metalloprotease 2 (MMP-2), MMP-14 and MMP-9, whereas it suppresses the invasion of osteosarcoma by suppressing MMP-2 activity via RhoA-JNK-c-Jun-MMP2 signaling pathway [49] [50] [51] [52] .
Yi et al [53] have demonstrated that atorvastatin can mitigate the pro-tumorigenic effect of microglia upon the glioma invasion and migration by down-regulating MT1-MMP expression in microglia. A potential mechanism of downregulating MT1-MMP in microglia is associated with the p38 MAPK signaling pathway. Fromigue et al [52] also reported that inhibiting HMG-CoA reductase via statins and decreasing RhoAGTPase prenylation reduces MMP2 activity in the JNK-cJun signaling pathway of osteosarcoma cells. Markovic et al [48] have found that glioma manipulates tumor-associated microglial cells through TLR signaling pathway for MT1-MMP expression, thereby promoting the expansion of glioma. The pro-tumorigenic effect of microglial cells serves as a target for the management of new brain tumors. 
EFFECT OF STATINS ON GLIOMA CELL MIGRATION
Although distant migration of glioma is rare, it also indicates the end-stage of the disease and a poor outcome. Glioma cell migration interferes with a good prognosis. Statins may play an important role in preventing glioma migration [15, 18, 20, 26, 31] .
However, the specific molecular mechanism remains elusive. Nawaz et al [56] have indicated Cbx7 potentiation within glioma cells leads to YAP/TAZ loss, which drives the transcriptome, as evidenced by the negative enrichment of the YAP/TAZ targets. Cbx7 can regulate SAPK/JNK activity via modulating CTGF, and this Hippo signaling pathway is evaluated by detecting YAP/TAZ-dependent transcriptional activity, which is less effective in the of migration of glioblastoma.
Yi et al [53] have demonstrated atorvastatin reduces the pro-tumorigenic effect of microglia upon the migration of glioma by down-regulating the expression level of MT1-MMP. Therefore, down-regulating MT1-MMP is regulated by p38 MAPK signaling pathway in microglia. Obara et al [57] have demonstrated that cerivastatin is capable of mediating FAK tyrosine phosphorylation and influencing different cell effects by interacting with several cell signaling pathways associated with cell migration. These studies support further research on statins, as a candidate, and targeting the signal transduction pathways related to glioblastoma biology probably serves as a potential treatment for glioma. Large sample size clinical trials of statins or drugs with similar structures are urgently required to enhance the quality of life of glioma patients. 
EFFECT
CLINICAL TRIAL PROGRESS
Many studies have confirmed that statins safe are and effective for treating glioma and other types of cancers. However, the results of clinical studies have been inconsistent and contrasting. Besides, the clinical efficacy of statins in patients with glioma has been controversial (Table 1) . Unfortunately, relevant data obtained from RCT are still lacking. A nationwide case-control study including 2656 patients and 18 480 healthy controls in Denmark proposed that the incidence of glioma is decreased among those with longterm use of statin their counterparts never use of statins, which is negatively associated with the intensity of statin administration [17] .
Another similar clinical trial including 339 GBM patients has demonstrated that statin use before diagnosis can decrease the HR of death. HR decreases over prolonged intensity and duration of pre-diagnostic statin use [19] . Therefore, longterm pre-diagnostic statin use may improve the survival of GBM patients. In contrast, Seliger et al [73] opposed of the notion that negative association exists between use of statins and risk of glioma in a case-control investigation from the UK-based Clinical Practice Research Datalink to analyze of the administration of statins among 2469 glioma patients and 24,690 healthy controls. Ferris et al [22] have found that both statins and non-steroidal anti-inflammatory drugs possess significantly inverse trends between the duration of drug use and glioma risks, and drug intake for longer than 120 months demonstrates the most significant associations for both medication types. Another preoperative statin use study included 78 patients taking statins preoperatively, while 206 patients did not. The results had similar progression-free survival before and after propensity score matching. Also, the mortality is similar between the two groups [74] . These studies were not RCTs. 
CONCLUDING REMARKS
Previous studies have suggested that statins can reduce the morbidity of glioma patients with longterm use and improve the clinical prognosis and prolong the survival time of glioma patients, which has been validated by numerous laboratory studies. In addition, clinical studies have yielded negative results. Nevertheless, these negative outcomes do not interfere with further evaluation of the safety and clinical efficacy of statins administration in glioma patients. Large-scale research and RCT studies are still urgently required to investigate the clinical benefits of statin use in glioma patients.
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